Browse by author
Lookup NU author(s): Dr John Bourke
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Patients with advanced malignancy are at an increased risk of cardiac arrhythmias, from their cancer and cardiotoxic treatments. Supportive care products co-administered should therefore not increase this risk. No clinically important cardiovascular effects are associated with the administration of granisetron over 30 s. To determine the effects of a rapid (I s) injection of granisetron, 3 mg, on measures of cardiac repolarisation, a pilot study was performed in 17 patients undergoing moderately/highly emetogenic chemotherapy at two centres. All received dexamethasone, 8-12 mg, infused over 30 min, followed immediately by granisetron and then chemotherapy. Twelve-lead electrocardiograms (ECGs) performed before granisetron treatment, 2 h later and the following day (I I patients) showed no differences in QTc(end max), QTc(apex max) or QT-interval dispersion between baseline and subsequent measurements, and there were no significant secondary adverse events. On this basis, granisetron should be considered the first-choice antiemetic for patients at increased risk of cardiac complications. (C) 2003 Published by Elsevier Science Ltd.
Author(s): Aapro M, Bourke JP
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
ISSN (print): 0959-8049
Altmetrics provided by Altmetric